We are live on ! Find out more
GLMD icon

Galmed Pharmaceuticals

22 hedge funds and large institutions have $8.36M invested in Galmed Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 2222 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

6% less capital invested

Capital invested by funds: $8.93M → $8.36M (-$575K)

33% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 6

Holders
22
Holders Change
Holders Change %
0%
% of All Funds
0.59%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
4
Increased
4
Reduced
6
Closed
4
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
6CM
1
683 Capital Management
New York
$2.66M
PWAM
2
Park West Asset Management
California
$2.02M -$10.4K -6 -0.5%
PA
3
Perceptive Advisors
New York
$755K
KCM
4
Knoll Capital Management
Florida
$654K
Goldman Sachs
5
Goldman Sachs
New York
$422K -$52.2K -30 -11%
SKK
6
Shepherd Kaplan Krochuk
Massachusetts
$376K
Geode Capital Management
7
Geode Capital Management
Massachusetts
$273K
Vanguard Group
8
Vanguard Group
Pennsylvania
$262K +$87K +50 +53%
CAD
9
Craig A. Drill
$160K -$904K -520 -86%
MC
10
Menta Capital
California
$145K +$5.22K +3 +4%
CA
11
CapWealth Advisors
Tennessee
$121K
ARTA
12
A.R.T. Advisors
New York
$118K -$8.7K -5 -7%
BIT
13
BlackRock Institutional Trust
California
$117K +$36.5K +21 +49%
Renaissance Technologies
14
Renaissance Technologies
New York
$109K -$59.1K -34 -36%
Morgan Stanley
15
Morgan Stanley
New York
$67K +$6.96K +4 +12%
Acadian Asset Management
16
Acadian Asset Management
Massachusetts
$38K +$36.5K +21 New
BA
17
BlackRock Advisors
Delaware
$21K +$19.1K +11 New
Wells Fargo
18
Wells Fargo
California
$20K
Bank of America
19
Bank of America
North Carolina
$5K
EDRE
20
Edmond de Rothschild (Europe)
Luxembourg
$4K +$3.48K +2 New
EDRH
21
Edmond de Rothschild Holding
Switzerland
$4K +$3.48K +2 New
UBS Group
22
UBS Group
Switzerland
$3K -$34.8K -20 -91%
VKH
23
Virtu KCG Holdings
New York
-$121K -71 Closed
SIM
24
Spark Investment Management
New York
-$111K -66 Closed
Deutsche Bank
25
Deutsche Bank
Germany
-$29K -17 Closed

GLMD Hedge Fund Activity: Q2 2015 in Review

22 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q2 2015, worth a combined $8.36M — down 6.4% from $8.93M a quarter earlier.

Fund positioning in GLMD was balanced in Q2 2015: 4 funds opened new positions, 4 closed out, 4 added to existing stakes and 6 trimmed.

The largest buyer was Vanguard Group, adding an estimated $87K. The largest seller was Craig A. Drill, cutting an estimated $904K.

  • 22 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q2 2015, unchanged from Q1 2015.
  • Funds reported $8.36M of Galmed Pharmaceuticals stock for Q2 2015, down 6.4% quarter-over-quarter.
  • 4 funds opened new Galmed Pharmaceuticals positions in Q2 2015 and 4 closed out, a net change of 0 holders.
  • The largest Galmed Pharmaceuticals buyer in Q2 2015 was Vanguard Group, an estimated $87K added.
  • The largest Galmed Pharmaceuticals seller in Q2 2015 was Craig A. Drill, an estimated $904K sold.

Based on aggregated 13F filings for Q2 2015.